GlassScriptPhysician profile
James C Hobley
NPI 1336114917
$4,179.59
in general payments reported to CMS, 2019-2025
31 companies · $728 in 2025
The $728 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $130 · 2021: $504 · 2022: $859 · 2023: $718 · 2024: $626 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $817.43 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $563.45 | 2019-2024 | Trulance, Xifaxan |
| Celgene Corporation | $403.11 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $285.81 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $269.75 | 2019-2024 | Entyvio |
| Boston Scientific Corporation | $156.74 | 2020-2022 | |
| Enterra Medical, INC. | $154.71 | 2023 | |
| Covidien LP | $133.01 | 2019 | |
| Pfizer INC. | $128.90 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $114.58 | 2021 | |
| Medtronic USA, INC. | $99.75 | 2019 | |
| Vivus LLC | $94.86 | 2022-2023 | Qsymia |
| Cook Medical LLC | $92.85 | 2019-2022 | |
| Genzyme Corporation | $86.39 | 2022-2025 | |
| Olympus America INC. | $83.34 | 2025 | Evis Exera III Video System Center, Gastrointestinal Videoscope, Evis Exera II Ultrasound Gastrovideoscope |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $81.44 | 2021 | |
| Ironwood Pharmaceuticals, INC | $70.95 | 2021-2023 | Linzess |
| Braintree Laboratories, INC. | $69.02 | 2019 | |
| Janssen Biotech, INC. | $68.00 | 2019-2024 | Tremfya |
| Ardelyx, INC. | $66.23 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $51.39 | 2021-2022 | |
| Qol Medical, LLC | $47.00 | 2023-2024 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $45.53 | 2024 | |
| Daiichi Sankyo INC. | $44.84 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $28.42 | 2022-2023 | Dificid |
| Medtronic, INC. | $27.41 | 2021 | |
| Redhill Biopharma INC. | $25.82 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $20.77 | 2025 | Iqirvo |
| Lilly USA, LLC | $18.70 | 2024 | Omvoh |
| Cumberland Pharmaceuticals, INC. | $15.08 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.